ImmunityBio, Inc. Common Stock
Here’s whether ImmunityBio, Inc. Common Stock (IBRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.30% over 10 days); RSI 62 — healthy momentum range; strong 1-year return of +247.8%; 3-month momentum positive (+7.9%). Concerns: declining volume on rally — weak conviction (0.80x 30d avg). Currently 37.3% off its 52-week high. Score: +6/7.
IBRX is in a confirmed uptrend, trading above both its 50-day ($7.73) and 200-day ($6.30) moving averages. An RSI of 61.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +247.8% compares to +20.5% for SPY (beat the market by 227.3%). The current 37.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.